Your Subtitle text
About Us
Envoy Therapeutics’ mission is to discover new drugs with superior efficacy and fewer side effects than existing treatments. The company’s bacTRAP® technology enables the identification of proteins in vivo that are produced by specific cell types without requiring the isolation of those cells. The technology is especially powerful in tissues of the brain, where many hundreds of cell types are intermingled. Because therapeutically modulating the activity of a specific cell type has until now been prevented by the inability to determine which proteins are uniquely expressed by that cell type, Envoy brings a new day in drug discovery.
Envoy has three highly recognized scientific founders, including Nobel Laureate and National Academy of Sciences member Paul Greengard, PhD.; Howard Hughes Medical Institute Investigator Nathaniel Heintz; and National Academy of Sciences member and Howard Hughes Medical Institute Investigator, Jeffrey Friedman, M.D., PhD.
These scientific founders bring great expertise in disciplines vital to Envoy’s missions including the biochemical regulation of brain cells and neurotransmitter receptors, the molecular mechanisms involved in obesity, body weight, appetite and fat storage, and the engineering of bacteria artificial chromosomes (BACs) by homologous recombination and transgenic technology. Our fourth founder and CEO, Brad Margus, is a seasoned executive with a strong track record in starting and building science based organizations, protecting new discoveries, raising capital, and partnering repeatedly with many of the world’s largest pharmaceutical companies.
We expect to make rapid progress by:
· identifying new, medically important, target proteins,
· building a portfolio of proprietary new drugs that modulate those proteins and fill unmet medical needs,
· demonstrating repeatedly the enormous power of our technology platform, and
· delivering successful results with a select number of partnerships with global pharmaceutical companies.
We’re passionate about creating and exploiting our completely new and unique drug discovery engine.
Envoy has three highly recognized scientific founders, including Nobel Laureate and National Academy of Sciences member Paul Greengard, PhD.; Howard Hughes Medical Institute Investigator Nathaniel Heintz; and National Academy of Sciences member and Howard Hughes Medical Institute Investigator, Jeffrey Friedman, M.D., PhD.
These scientific founders bring great expertise in disciplines vital to Envoy’s missions including the biochemical regulation of brain cells and neurotransmitter receptors, the molecular mechanisms involved in obesity, body weight, appetite and fat storage, and the engineering of bacteria artificial chromosomes (BACs) by homologous recombination and transgenic technology. Our fourth founder and CEO, Brad Margus, is a seasoned executive with a strong track record in starting and building science based organizations, protecting new discoveries, raising capital, and partnering repeatedly with many of the world’s largest pharmaceutical companies.
We expect to make rapid progress by:
· identifying new, medically important, target proteins,
· building a portfolio of proprietary new drugs that modulate those proteins and fill unmet medical needs,
· demonstrating repeatedly the enormous power of our technology platform, and
· delivering successful results with a select number of partnerships with global pharmaceutical companies.
We’re passionate about creating and exploiting our completely new and unique drug discovery engine.
